KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2554-2564

  Kelber, Jonathan A ^a,c   Reno, Theresa ^a,c   Kaushal, Sharmeela ^c   Metildi, Cristina ^c,d   Wright, Tracy ^a,c   Stoletov, Konstantin ^a,c   Weems, Jessica M ^a,c   Park, Frederick D ^a,b,c   Mose, Evangeline ^c   Wang, Yingchun ^e   Hoffman, Robert M ^d,f   Lowy, Andrew M ^c,d   Bouvet, Michael ^c,d   Klemke, Richard L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^f ANTICANCER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PROTEIN TYROSINE KINASE; PSEUDOPODIUM ENRICHED ATYPICAL KINASE 1 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME LOCALIZATION; ENZYME REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-2; GENES, RAS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN PP60(V-SRC); PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84861162319     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3552     Document Type: Article

References (38)

1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49. (Pubitemid 43727584)
2. Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011;223:295-306.
3. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56:1134-52. (Pubitemid 47123247)
4. Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, et al. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 2011;30:2123-34.
5. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007;13:3356-62. (Pubitemid 46944923)
6. Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006;12:4925-32. (Pubitemid 44338580)
7. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Zunino F, Calcaterra C, et al. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 2008;31:537-44.
8. Buchler P, Reber HA, Buchler MC, Roth MA, Buchler MW, Friess H, et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 2001;5:139-46. (Pubitemid 33652051)
9. Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 2011;17:483-93.
10. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. MolCancer Res 2005;3:413-23. (Pubitemid 41045591)
11. Zhao S, Wang Y, Cao L, Ouellette MM, Freeman JW. Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer 2010;127:2076-87.
12. Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, et al. Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. Proc Natl Acad Sci U S A 2010;107:10920-5.
13. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34. (Pubitemid 35425239)
14. Brandt R, Wong AM, Hynes NE. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 2001;20:5459-65. (Pubitemid 32889482)
15. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50. (Pubitemid 38050041)
16. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23. (Pubitemid 47355323)
17. Snyder CS, Kaushal S, Kono Y, Cao HS, Hoffman RM, Bouvet M. Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2009;9:106.
18. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009;6:e1000046.
19. Carriere C, Seeley ES, Goetze T, Longnecker DS, Korc M. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A 2007;104:4437-42. (Pubitemid 47186244)
20. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806. (Pubitemid 41400779)
21. Deryugina EI, Quigley JP. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 2008;130:1119-30.
22. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2008;27:1951-60. (Pubitemid 351430826)
23. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008;55:2016-27.
24. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996;27:119-24. (Pubitemid 26049464)
25. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-8. (Pubitemid 28414054)
26. Marcotte R, Zhou L, Kim H, Roskelly CD, Muller WJ. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 2009;29:5858-71.
27. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homoand heterodimers. Mol Cell Biol 1999;19:6845-57. (Pubitemid 29441868)
28. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010;316:1083-100.
29. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004;22:706-12. (Pubitemid 40064730)
30. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-3.
31. Kelber JA, Klemke RL. PEAK1, a novel kinase target in the fight against cancer. Oncotarget 2010;1:219-23.
32. Ridley AJ. Life at the leading edge. Cell 2011;145:1012-22.
33. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci 2011;17:2561-71.
34. Linding R, Jensen LJ, Pasculescu A, Olhovsky M, Colwill K, Bork P, et al. NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res 2008;36:D695-9. (Pubitemid 351149809)
35. Lu XL, Cao X, Liu XY, Jiao BH. Recent progress of Src SH2 and SH3 inhibitors as anticancer agents. Curr Med Chem 2010;17:1117-24.
36. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909. (Pubitemid 37328891)
37. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-8. (Pubitemid 351601205)
38. Hann A, Gruner A, Chen Y, Gress TM, Buchholz M. Comprehensive analysis of cellular galectin-3 reveals no consistent oncogenic function in pancreatic cancer cells. PLoS One 2011;6:e20859.